semaj83/ctmatch_classification huggingface dataset:
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Ankylosing Spondylitis Active and severe ankylosing spondylitis Ankylosing spondylitis refractory to standard anti-rheumatic treatment Between 18 and 70 years of age  Prior exposure to any TNF-inhibitor, including etanercept DMARDs (other than hydroxychloroquine, methotrexate and sulphasalazine) within 4 weeks of study drug initiation Dose of NSAIDs changed within two weeks of study drug initiation
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Rheumatoid Arthritis Diagnosis of RA Currently receiving an adequate dose of methotrexate (MTX) for treatment of RA Active RA at time of screening and baseline  Previous or current treatment with etanercept (ETN), other tumor necrosis factor-alpha inhibitors, or other biologic agents Concurrent treatment with a DMARD, other than MTX, at screening Receipt of any DMARD, other than MTX, within 3 months before screening
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 1.5-19.0,  Juvenile Idiopathic Arthritis Fulfills International League Against Rheumatism (ILAR) for SJIA Duration of SJIA lasting at least 6 weeks since onset Active disease as defined by at least two joints with active disease Not currently receiving methotrexate OR if taking methotrexate, the dose has remained stable or has been discontinued for 4 weeks prior to screening Has never received certain biologics OR if previously received biologics, discontinued etanercept for at least 4 weeks prior to screening and discontinued infliximab or adalimumab for at least 8 weeks prior to screening Not currently receiving corticosteroids OR if taking oral corticosteroids, the dose has remained stable between 2 and 60 mg/day for at least 2 weeks prior to screening  Past treatment with anakinra, rilonacept, or other biologic IL-1 inhibitor Treatment with other disease-modifying antirheumatic drugs (DMARDs) including, but not limited to, azathioprine, sulfasalazine, cyclosporine, and thalidomide within 4 weeks of screening Treatment with leflunomide without cholestyramine washout at the end of therapy Treatment with cyclophosphamide within 3 months of study entry Treatment with tacrolimus or tocilizumab within 4 weeks of study entry Treatment with rituximab within 6 months of study entry Treatment with intravenous immunoglobulin (IVIG) within 4 weeks of screening Kidney disease AST or ALT levels more than two times the upper limit of normal Bilirubin levels higher than 1.5 mg/dl
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) and in accordance with local guidelines Patients eligible to anti-TNF therapy Patients naïve to anti-TNFa drugs Patients with radiography (hands and feet) executed by 6 months before the baseline or at baseline according to modified Sharp Van der Hejde method [Sharp JT et al. 1985; Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form  Patients with tumors Patients already included in clinical trials
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Polymyalgia Rheumatica Rheumatoid Arthritis Rheumatic Disease Patients signing Informed Consent  Patients less than 50 years old
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis adult patients >/= 18 years of age active moderate or severe rheumatoid arthritis of <10 years duration with inadequate response to methotrexate or anti-TNF on methotrexate treatment for at least 10 weeks, at least 8 weeks on stable dose patients receiving oral corticosteroids and/or NSAIDs should be at stable dose for 4 weeks  rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA functional class IV by ACR classification history of inflammatory joint disease other than RA previous treatment with cell-depleting therapies, abatacept or rituximab active current or history of recurrent infection, or any major episode of infection requiring hospitalization or treatment with iv antibiotics <4 weeks or oral antibiotics <2 weeks prior to screening
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Polymyalgia Rheumatica clinical diagnosis of polymyalgia rheumatica  decompensated diabetes mellitus decompensated arterial hypertension
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Abnormality Inflammation Rheumatism gp Suspects or affected by rheumatoid polyarthritis Morning articular Stiffness of at least 15 minutes Arthalgias or Arthritises of at least three joints(articulations), among which those of the hand Possible rheumatoid Presence of a factor(mailman) and\or Antibody anti peptides positive citrullinés Typical possible radiological Hurts on the standard clichés(pictures) of the reached(affected) joints(articulations) gp Affected by stiffening spondylitis with axial and peripheral infringement   Lumbago and steepness lumbar vertebra inflammatory. 2. Arthralgias and\or peripheral arthritises 3. Possible presence of an allèle HLA 4. Possible presence of a sacro-illite 5. Absence of the other rheumatic markers gp Affected by connectivity with anti-nuclear antibody positive and / or specific antibodies, suffering of polyarthralgias with or without arthritis gp Healthy control gp Presenting a degenerative osteoarthritis of the wrist traumatic comment, noticed radiologically, which will serve as not inflammatory control  Claustrophobia metallic foreign bodies pacemakers The pregnant women parturients or who breast-feed are excluded from the study
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis Signed, IRB-approved, written informed consent Subjects can be of either gender but must be more than 18 years old Subjects must fulfill the disease activity for RA and a DAS28 will be assessed at baseline and at 2 months after rituximab therapy Aim A Eligible subjects must meet for RA and have an inadequate response to MTX defined as DAS28 >5.1. They must have been on a steady dose of MTX (between 15 and 20 mg /week for a minimum of 8 weeks). Subjects must have evidence of knee synovitis on exam to enter the study Aim B Subjects must have demonstrated a response to a TNF antagonist as evidenced by a DAS score <2.8 or <4 tender and swollen joints. Flare will be defined as a DAS 28 >5.1 of more than 8 swollen and tender joints. Subjects must have evidence of knee synovitis to enter the study. Subjects will be off etanercept, infliximab or adalimumab for 4 weeks before starting BCDT. All subjects must also be on a stable dose of DMARD (MTX, leflunomide, azulfidine, hydroxychloroquine) for 8 weeks before entry into the study  Patients will be excluded for medical or other reasons at the discretion of the investigators. The reasons for the must be recorded, e.g. risk of non-compliance, vulnerability, medically unstable, etc Active systemic disorders or inflammatory conditions (i.e., chronic infection with hepatitis B, hepatitis C or HIV) other than the conditions being studied Patients with a plasma creatinine > 1.5 mg/dl Aim B Subjects with an allergy to corticosteroids will be excluded from the study Anyone answering yes to the following questions will be excluded Do you have a history of Cardiac (Heart) pacemaker or defibrillator? Cardiac (Heart) valve replacement or prosthesis? Aneurysm clips from brain surgery?
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Recurrent Melanoma Stage IV Melanoma Patients with metastatic melanoma who have measurable disease ECOG PS 0 or 1 Adequate bone marrow function WBC >= 3,000 Hgb >= 9 Plt >= 100 Adequate hepatic function, defined by the following parameters Total bilirubin WNL unless associated with hepatobiliary metastases or Gilbert syndrome, then total bilirubin =< 2 x ULN Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN unless associated with hepatic metastases, then ALT and AST =< 5 x ULN Signed, written informed consent
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Polymyalgia Rheumatica patients with PMR, diagnosed according to the of Bird et al  patients with arthritis patients with giant cell arteritis patients with Parkinson's disease patients with hypothyroidism patients with scapulohumeral periarthritis patients with fibromyalgia patients unable to cooperate
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-49.0,  Spondylitis, Ankylosing Diagnosis of axial spondyloarthritis as defined by Assessments in Ankylosing Spondylitis (ASAS)criteria Active symptoms defined as Ankylosing Spondylitis Disease Activity Index{BASDAI) > or = 4 Axial symptoms of back pain with a less than favorable response to on steroidal anti inflammatory drugs at optimal dosage for greater than 4 weeks  Evidence of current or recent episode of uveitis Evidence of IBD flare within 6 months Previous treatment with an anti Tumor necrosis factor(TNF) Active tuberculosis Radiographic sacroiliitis grade 3-4 unilaterally or >= 2 bilaterally
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis Ankylosing Spondylitis Psoriatic Arthritis Patients aged ≥ 18 years for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis Patients must fulfill international and national guidelines for the use of a biological disease modifying antirheumatic drug in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (chest x-ray and interferon gamma release assay or purified protein derivative-skin test negative for tuberculosis). In addition one of the following must be fulfilled unsatisfactory disease modifying antirheumatic drug response defined as failure to treatment with at least two disease modifying antirheumatic drugs including Methotrexate in patients with rheumatoid arthritis or psoriatic arthritis unsatisfactory non steroidal antiinflammatory drug response in patients with ankylosing spondylitis or unsatisfactory response to prior biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis or ankylosing spondylitis  Patients who meet contraindications as outlined in the latest version of the Humira syringe® summary of product characteristics and Humira Pen® summary of product characteristics Patients participating in another study program or clinical trial Patients who have been treated with Humira before
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis Must have a documented diagnosis of Rheumatoid Arthritis (1987 American College of Rheumatology Criteria) with onset of signs/symptoms of disease ≥ 4 months of duration from randomization Must be receiving treatment on an outpatient basis Must have active disease despite current methotrexate treatment as defined below ≥ 6 swollen joints (66 swollen joint count) AND ≥ 6 tender joints (68 tender joint count) -. Must meet at least one of the four lab requirements below High Sensitivity C-Reactive Protein (hsCRP) ≥ 10 mg/L Erythrocyte Sedimentation Rate (ESR) > 28 mm after the first 1 hour Positive for Rheumatoid Factor (RF) Positive for Anti-cyclic Citrullinated Peptide (anti-CCP) antibodies  Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization Rheumatic autoimmune disease other than Rheumatoid Arthritis, including systemic lupus erythematosus, mixed connective tissue disease, scleroderma, polymyositis or significant systemic involvement secondary to Rheumatoid Arthritis (eg, vasculitis, pulmonary fibrosis or Felty syndrome). Sjögren syndrome secondary to Rheumatoid Arthritis is allowable Functional Class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis Prior history of, or current, inflammatory joint disease other than Rheumatoid Arthritis (eg, gout, reactive arthritis, psoriatic arthritis, ankylosing spondylitis, Lyme disease) Receiving treatment with Disease-modifying antirheumatic drugs (DMARDs) (other than methotrexate), including biologic Disease-modifying antirheumatic drugs (DMARDs)Previous use is only allowed after adequate washout prior to randomization Inadequate response to treatment with an anti-tumor necrosis factor (anti-TNF) agent. Patients who terminated previous anti-tumor necrosis factor (anti-TNF) treatment due to cost or safety reason, such as discomfort with the subcutaneous injections, may participate in this study after adequate washout Treatment with any investigational agent within four weeks (or five half-lives of the investigational drug, whichever is longer) of screening Previous treatment with any cell depleting therapies, including investigational agents Treatment with intravenous gamma globulin, plasmapheresis or Prosorba® column within 6 months of baseline Intra-articular or parenteral corticosteroids are not allowed within 6 weeks prior to randomization
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Osteoarthritis Clinical diagnosis of primary osteoarthritis of the knee(s) Presently receiving prescribed oral or topical analgesics for a minimum duration of two weeks prior to enrollment  Arthritis other than primary osteoarthritis Treatment with disease-modifying antirheumatic drugs (DMARDS), methotrexate or biologics Subtotal or total joint replacement in the affected knee Chronic severe pain of other causes that in the opinion of the investigator may require long-term analgesia or confound the present study Currently enrolled in a clinical trial or who have participated in a clinical trial within the past 30 days
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Axial Spondyloarthritis Male and female subjects aged 18 years and over at the time of consent to the study Diagnosis of SpA, as defined by the ASAS for axial SpA Axial involvement refractory to previous or current intake of NSAIDs, defined as at least 2 NSAIDs at maximum tolerated dose determined from past medical history taken for a duration of > 1 month (for both NSAIDs combined) before the Screening visit Active axial involvement defined by mini  Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial Subjects who have received any previous treatment with etanercept or other TNFα inhibitors or biologic agents Subjects with a known or expected allergy, contraindication, or hypersensitivity to etanercept or its excipients
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-25.0,  Exercise Anaphylaxis Young healthy females Between 18-25 years old No on medication (this includes contraceptives)  Medication use (including oral contraceptives) Amenorrhoea High blood pressure Very active (>3 hours per week of organized physical activity)
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 20.0-95.0,  Osteonecrosis Osteoarthritis Osteoarthritis of hip joint requiring total hip arthroplasty  Neurologic disorders affecting motor function of lower extremity foot and ankle disorders limiting ambulation of the patient Patients with bone metabolic disorders other than osteoporosis which prevents normal bone metabolism Multi-systemic inflammatory arthritis which debilitates patients other than hip joint